{"analyses":[{"ciLowerLimit":"0.07","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.50","groupDescription":"Median time to engraftment","groupIds":["OG001"],"nonInferiorityType":"OTHER","paramType":"percentage","paramValue":"0.24"}],"classes":[{"categories":[{"measurements":[{"comment":"Two few observations to calculate upper limit","groupId":"OG000","lowerLimit":"12","upperLimit":"NA","value":"12"},{"groupId":"OG001","lowerLimit":"12","upperLimit":"14","value":"13"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"description":"Estimated Median Time to Neutrophil Engraftment, ANC 500","dispersionType":"95% Confidence Interval","groups":[{"description":"G-CSF 16 mcg/kg/day for 9 days; Bortezomib 1.3 mg/m2 IV on day 6. Blood draws and apheresis on days 5-9.","id":"OG000","title":"Arm A Standard of Care Mobilization"},{"description":"G-CSF16 mcg/kg/day for 8 days; Bortezomib on days 4 and 7. Blood collection on days 4 \\& 8, apheresis on days 5-8.","id":"OG001","title":"Arm B Alternative Mobilization"}],"paramType":"MEDIAN","populationDescription":"Evaluable patients","reportingStatus":"POSTED","timeFrame":"Up to 6 months","title":"Time to Neutrophil Engraftment","type":"SECONDARY","unitOfMeasure":"days to ANC 500"}